Cellectar Biosciences, Inc.
Healthcare · Biotechnology
CLARITY GRADE · crash risk, updated Tuesdays
week of Nov 16
FLAWED
8 weeks at this grade
| Fact | This stock | Similar stocks that dropped 20%+ |
|---|---|---|
| Price swings, last 60 days | wilder than 68% of stocks under $10B | 29 vs typical 23 of 100 |
| Distance below its 52-week high | 75% below | 37 vs typical 23 of 100 |
| Finances vs industry peers (return on equity, operating cash flow) | return on equity above 24% of peers, cash flow yield above 4% | 32 vs typical 23 of 100 |
| New shares issued over the last year | share count +136.8% | 34 vs typical 23 of 100 |
| Trading heat vs peers (shares traded / shares outstanding) | more than 34% of peers |
Big drops and big rises were about as common.
Past stocks scored each week from January 2024 to June 2026, using only data available at the time, then checked 60 trading days later. A grade is about holding up, not about gains, and it is not a buy or sell signal. How the grades are tested